Matinas BioPharma Holdings, Inc., a biopharmaceutical company, is identifying and developing novel pharmaceutical products to treat abnormalities in blood lipids, referred to as dyslipidemia, and cardiovascular and metabolic diseases. Led by an experienced management team and a board of directors with a history of building pharmaceutical companies, Matinas is focused on creating the next generation of omega-3-fatty-acid-based pharmaceutical products. For more information, visit the company’s website at www.matinasbiopharma.com.